Advertisement

  • Loading metrics

Open Access

Review

Review articles synthesize the best available evidence on a topic relevant to the pathogens community.

See all article types »

Manipulation of Costimulatory Molecules by Intracellular Pathogens: Veni, Vidi, Vici!!

Abstract

Some of the most successful pathogens of human, such as Mycobacterium tuberculosis (Mtb), HIV, and Leishmania donovani not only establish chronic infections but also remain a grave global threat. These pathogens have developed innovative strategies to evade immune responses such as antigenic shift and drift, interference with antigen processing/presentation, subversion of phagocytosis, induction of immune regulatory pathways, and manipulation of the costimulatory molecules. Costimulatory molecules expressed on the surface of various cells play a decisive role in the initiation and sustenance of immunity. Exploitation of the “code of conduct” of costimulation pathways provides evolutionary incentive to the pathogens and thereby abates the functioning of the immune system. Here we review how Mtb, HIV, Leishmania sp., and other pathogens manipulate costimulatory molecules to establish chronic infection. Impairment by pathogens in the signaling events delivered by costimulatory molecules may be responsible for defective T-cell responses; consequently organisms grow unhindered in the host cells. This review summarizes the convergent devices that pathogens employ to tune and tame the immune system using costimulatory molecules. Studying host-pathogen interaction in context with costimulatory signals may unveil the molecular mechanism that will help in understanding the survival/death of the pathogens. We emphasize that the very same pathways can potentially be exploited to develop immunotherapeutic strategies to eliminate intracellular pathogens.

Citation: Khan N, Gowthaman U, Pahari S, Agrewala JN (2012) Manipulation of Costimulatory Molecules by Intracellular Pathogens: Veni, Vidi, Vici!! PLoS Pathog 8(6): e1002676. https://doi.org/10.1371/journal.ppat.1002676

Editor: Tom C. Hobman, University of Alberta, Canada

Published: June 14, 2012

Copyright: © 2012 Khan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The authors acknowledge CSIR (India) and DBT (India) for financial support. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Introduction

The immune system is highly evolved to combat and eliminate pathogens. However, some pathogens can successfully subvert the host immune system to establish their intracellular survival via strategies such as the disguise or sequestration of antigens, molecular mimicry, immunosuppression, circumvention of complements and cytokines cascade, blockade of antigen presentation, escape from apoptosis and autophagy, and modulation of costimulatory signals [1].

T cells and antigen-presenting cells (APCs) play crucial roles in eliminating intracellular pathogens. The optimal activation of naive T cells is achieved by occupancy of T-cell receptor (TCR) by the peptide-MHC complex displayed on the surface of APCs, delivery of costimulatory signals, and the presence of proinflammatory cytokines [2]. The expression of costimulatory molecules on APCs is critical in shaping the extent and nature of the immune response. Thus, an encounter of T cells with peptide-MHC can result in two discrete events: (a) T-cell proliferation and differentiation into effector cells; (b) or anergy or apoptosis. The question of which of these outcomes transpires is determined by the delivery of appropriate costimulatory signals [3]. An array of costimulatory molecules is displayed on the surface of APCs (CD80/B7-1, CD86/B7-2, CD83, CD40, PDL-1, DC-SIGN, 4-1BBL, etc.) and T cells (CD28, CTLA-4, CD40L, PD-1, OX40, 4-1BB, etc). The level of the expression of the costimulatory molecules may play an important role during the course of acute disease and its remission or relapse. Hence, modulation of these molecules by pathogens can help them to establish their existence in the host.

Here we elaborate the mechanism by which pathogens such as Mtb, HIV, and Leishmania sp., employ molecules viz. CD28, CD40, CD40L, CD80, CD86, CTLA-4, PD1, PDL-1, etc., to break the code of costimulation to establish chronic infection. The organisms in consideration are representatives of successful pathogens from the class of bacteria, virus, and parasites. It appears that these pathogens adopt a common evolutionarily convergent mechanism to evade host immune reaction. This review provides insights into the mechanism by which pathogens suppress host immunity by modulating the expression of costimulatory molecules. We also suggest avenues of therapeutic intervention by exploiting costimulatory pathways for treating infections.

The Paradigm Shift in the Biology of Costimulation

The unilateral “help to T-cell” lymphocentric paradigm of costimulatory pathways has currently evolved into a bilateral signaling model that influences the activity of both T cells and APCs during their interaction (Figure 1) [4], [5]. Costimulatory molecules of CD80/CD28, tumor necrosis factor (TNF)/TNFR, and TIM superfamilies have unmasked the plethora of the possible ligand-receptor interactions that has expanded the understanding of regulation of the immune responses mediated by APCs and T cells. For example, a positive regulator like CD40L (on T cells) when associated with CD40 (on APCs), not only activates T cells but also results in the activation of dendritic cells (DCs); a process that is popularly called “T-cell licensing” [6]. Similarly, ligation of CD28 with CD80 and CD86 is known to induce the secretion of interleukin-6 (IL-6) and interferon-γ (IFN-γ) by DCs and activation, proliferation, and differentiation of B cells [5], [7], [8]. It is reported that 4-1BBL expressed on DCs, binds to 4-1BB on T cells, to bolster DCs help to T cells [9]. Many reports have highlighted the inhibitory roles of CTLA-4 (CD152) and PD-1 (expressed on T cells) with ligands CD80/CD86 and PDL-1/PDL-2 (on APCs), respectively [10], [11]. It clearly suggests that costimulation not only amplifies the magnitude of the activation of T cells and APCs, but fine tunes the immune response as well, thereby controlling the hyperactivation.

thumbnail
Download:
Figure 1. Immune response against intracellular pathogens.

(A) PRRs of APCs sense pathogens that result in the activation of APCs. (B) This leads to enhanced antigen presentation, upregulation of costimulatory molecules, and secretion of proinflammatory cytokines that promote the activation of T cells. The activated T cells help in elimination of the pathogens. (C) Engagement of costimulatory molecules on APCs by T cells also results in “bidirectional signaling” that activates APCs to restrict the growth of pathogens.

https://doi.org/10.1371/journal.ppat.1002676.g001

Modulation of Costimulatory Molecules by Bacteria

Intracellular pathogens like Mtb, Mycobacteria avium, M. leprae, Salmonella typhi (S. typhi), Helicobacter pylori (H. pylori), etc., infect both macrophages and DCs. These cells recognize bacterial components known as pathogen-associated molecular patterns (PAMPs) through their pathogen recognition receptors (PRRs). This triggers innate immunity that initiates antimicrobial defense mechanisms involving autophagy, apoptosis, release of antimicrobial compounds like IFN-γ and TNF-α, etc. [12]. It is followed by activation of adaptive immunity. The adaptive immune response, personified by specificity and memory, involves the clonal selection of B cells and T cells that confer humoral immunity (HI) and cell-mediated immunity (CMI) to pathogens, respectively. Pathogen-specific Th1 cells release cytokines, especially IFN-γ and TNF-α, which plays an imperative role in activating infected macrophages and restraining the microbial growth [13]. Further, ligation of CD80/CD86 with CD28 is essential for preventing apoptosis in T cells [7], [14]. Moreover, CD40/CD40L interaction results in efficient IL-12 production together with an upregulation of costimulatory molecules, in addition to enhanced antigen presentation by APCs thereby leading to a boosted T-cell response (Figure 1) [6], [15]. Hence, interference in the down-modulation of any of these pathways by the pathogens would be detrimental to the host.

Mtb is one of the most successful pathogens in the history of mankind. There are numerous reports indicating the role of mycobacteria in downregulating the expression of CD80, CD86, and CD40 on APCs [16], [17]. A recent study showed, albeit for BCG, that MHC-II, CD80, CD86, and CD40 are down-tuned during chronic phase of infection [16]. In such studies, it is important to delineate the expression of these molecules on infected versus non-infected cells, as by-stander inflammation could interfere in the interpretation of results. An elegant study demonstrated that the expression of costimulatory molecules and MHC are downregulated in macrophages infected with fluorescent reporter bacteria [16], [18]. In contrast, others suggested the augmentation of costimulatory molecules upon infection [19]. This discrepancy may be primarily dependent on the strain, system, or time-point of the study.

Downregulation of CD80/CD86 or upregulation of CTLA-4 by bacteria on APCs may induce anergy/apoptosis of interacting T cells [20], [21]. Defect in this signaling pathway is known to paralyze the release of IL-2, which may compromise the generation of T-cell memory [22]. Impediment in CD28 signaling interferes in IFN-γ production and hence promotes the survival of pathogens. It has been reported that M. leprae obstructs CD28/B7 signaling pathway for rendering antigen-specific T cell unresponsive in lepromatous leprosy patients [21]. Recently, the importance of CD80/CD86 in controlling mycobacterial infection has been demonstrated in CD80/CD86 double knockout mice [23]. The down-modulation of CD80/CD86 in chronic phase of the infection suggests that mycobacteria may actively exploit this pathway to anergize the T cells (Figure 2). Protective CMI is always associated with the release of chemokines and migration of immune cells to the site of infection. Mtb impair chemokines secretion by interfering with the CD28-B7 signaling pathway thereby obstructing the surveillance of immune cells and enhancing the propagation of the bacterium [24], [25]. It has been shown that the most abundant cell wall lipid trehalose 6, 6′-dimycolate (TDM) of Mtb and MTSA-10 inhibit the expression of costimulatory molecules on the surface of the macrophages [26], [27]. Similarly, CD40-CD40L interaction is very important in mediating efficient protection against mycobacteria [28]. Indeed, it has been shown in vitro and in lepromatous patients that CD40 is downregulated by M. leprae [29], [30]. There is indirect evidence indicating the involvement of Mtb manipulating CD40/CD40L expression. In humans, CD40L expression on Th1 cells of tuberculosis (TB) patients has been correlated with the intensity of IFN-γ secretion [31]. However, CD40 but not CD40L knockout mice are susceptible to Mtb infection [32], [33]. It is reported that the heat shock protein 70 (HSP70) of Mtb acts as an alternate ligand for CD40. Corroboratively, over-expression of HSP70 interferes with long-time persistence of Mtb and allows its clearance [34]. Interestingly, in chronic mycobacterial infections, CD40 is suppressed on infected cells [16]. Therefore, it is intriguing to speculate that in the chronic phase of infection, mycobacteria may hamper CD40 expression or manipulate CD40L signaling through binding with HSP70 instead of CD40L in order to evade host defense mechanisms.

thumbnail
Download:
Figure 2. Pathogens modulate the expression of costimulatory molecules for their survival.

Sensing of pathogens through PRRs triggers the activation of APCs. (A) Costimulatory molecules, which act as the second signal for T-cell activation, are upregulated on infected cells. Persistence of intracellular pathogens modulates the expression of costimulatory molecules, such as downregulation of CD40/CD80/CD86 and upregulation of PDL-1 on infected APCs. Similarly, retarding the exhibition of CD28/CD40L augments PD-1/CTLA-4 on T cells. (B) Interaction of T cells with the infected APCs impairs the function of T cells by inducing anergy, apoptosis, or exhaustion. (C) Lack of T-cell help impedes the activity of APCs, eventually enhancing the survival of pathogens.

https://doi.org/10.1371/journal.ppat.1002676.g002

Mycobacteria can upregulate the expression of PD-1 and its ligands PDL-1/PDL-2 [35]. Several studies have shown that T cells and natural killer (NK) cells from TB patients have increased PD-1 expression [36], [37]. Blockade of PD-1 interaction with PDL-1/PDL-2 enhances immune response. These observations suggest that mycobacteria may exploit PD-1 and PDL-1/PDL-2 pathways to dampen the host immune responses. In contrast, some studies have suggested that these pathways may be involved in controlling exuberant T-cell responses in TB and hence may be beneficial for both the host and the pathogen [36], [38], [39]. Mtb retards the development and maturation of monocyte-derived DCs to limit the immune response [40]. These immature DCs have a tolerogenic effect in vivo that can result in the generation of regulatory T cells (Tregs). Tregs can restrain the proliferation of naive and memory T cells, thereby suppressing pre-existing T-cell immunity [41], [42].

Besides mycobacteria, many other pathogens can exploit CD80/CD86-CD28/CTLA-4 pathways for their persistence (Table 1). H. pylori causes chronic infection in the gut resulting in peptic ulcers. Further, it is known to induce the expression of CTLA-4, resulting in the anergy of T cells and poor clearance of the bacteria [43]. Yersinia pseudotuberculosis decreases CD86 expression on B cells and impedes the function of both B cells and T cells [44]. S. typhi is known to suppress ICAM-1 and as a consequence reduces the antigen uptake by APCs and inadequate T-cell response [45], [46]. H. pylori diminishes the expression of CD40L on T cells and therefore employs CD40/CD40L pathway for its survival. Furthermore, it upregulates PDL-1 expression on gastric epithelial cells and inhibits the activation of T cells recruited to gastric mucosa [47]. In addition, it has been reported that PDL-1 upregulation not only blocks T-cell proliferation and IL-2 secretion, but also promotes the development of Tregs [48]. Bordetella pertussis and B. bronchiseptica decrease the manifestation of CD40 and ICAM-1 on DCs, and subsequently, render DCs tolerogenic and promote chiefly Tregs but not Th1 cells [49], [50]. Hence, costimulatory molecules could serve as attractive targets for bacteria to modulate in order to prolong their own survival.

thumbnail
Download:
Table 1. Exploitation of costimulatory molecules by intracellular pathogens.

https://doi.org/10.1371/journal.ppat.1002676.t001

Modulation of Costimulatory Molecules by Viruses

To counter viral infestation, the vertebrate immune system has evolved complex antiviral innate and adaptive immune mechanisms. Some of the spectacular examples to limit viral replication by the host cells are the production of interferons, NK cell-mediated lysis, and apoptosis of the infected cells [51], [52]. Adaptive antiviral immunity relies greatly on the lysis of infected cells by cytotoxic CD8+ T cells and neutralizing antibodies secreted by B cells.

HIV is a retrovirus that is responsible for 1.9 million deaths annually [53]. It predominantly infects CD4+ T cells. Further, it invades DCs, monocytes, and macrophages expressing CD4 and one of its coreceptors CCR5 or CXCR4 [54]. Additionally, HIV can bind to DC-SIGN and mannose receptors [55]. However, the virus preferentially replicates in the activated HIV-specific CD4+ T cells [56]. Indeed, excessive loss of CD4+ T cells is the hallmark of HIV infection [57]. Like many other intracellular pathogens, HIV efficiently exploits the costimulatory molecules to override the immune responses. Its infection is associated with decreased expression of CD40L on CD4+ T cells [58]. Upon activation, CD4+ T cells from individuals with progressive disease show very little upregulation of CD40L, which corroborates with their inability to help APCs and failure to induce IL-12 in DCs [59]. Further, CD40-CD40L interaction has been demonstrated to be important in engendering a robust HIV-specific CD8+ T-cell response. Furthermore, HIV interferes in the CD40 signaling pathway in B cells and hinders T cell help, thereby impairing the secretion of IgG and IgA antibodies [60], [61]. AIDS patients suffer from a defective humoral immunity, which may be due to loss of T-cell function, or B-cell intrinsic defects [62], [63]. HIV upregulates Fas and FasL (members of TNF superfamily) on CD8+ T cells and APCs, respectively, which leads to the apoptosis of the interacting CD8+ T cells [64], [65]. Thus, in HIV infections, the hunter becomes the hunted!

During viral infections, continual expression of CD80/CD86 on DCs is decisive to maintain the effector function of CD8+ T cells [66]. Intriguingly, HIV downregulates the expression of CD80/CD86 and their ligand CD28 on infected APCs and T cells, respectively [67], [68]. The expression of costimulatory molecules such as 4-1BBL, CD70, OX40, and OX40L is affected during HIV-1 infection [9], [69]. Measles, herpes, and hepatitis C viruses (HCV) retard the expression of CD80, CD86, CD25, CD83, and CD40 that leads to poor CD8+ T-cell priming [70]–[72]. In addition, Herpes virus suppresses ICAM-1 on APCs, thereby obstructing immunological synapse with T cells [73].

Chronic viral infections are associated with loss of function in T cells, a phenomenon popularly known as T-cell exhaustion. Exhausted T cells highly express PD-1 and have poor effector function [74]. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression [75]. PD-1 is known to make CD8+ T cells more susceptible to Fas-mediated lysis [76]. Signaling through PD-1 can suppress IL-2 secretion by CD8+ T cells. IL-2 is known to rescue T cells from anergy and boost the memory response [77]. In addition, upregulation of PDL-1 on APCs during HIV or hepatitis B virus (HBV) infection supports the survival of pathogens (Table 1) [78], [79]. In essence, viruses can exploit costimulatory molecules in restraining the function of both T cells and APCs.

Modulation of the Expression of Costimulatory Molecules by Intracellular Protozoan Parasites

T cells play a significant role in controlling the protozoa-inflicted diseases like malaria, visceral leishmaniasis, and trypanosomiasis. Humoral responses play a less important role. However, complement-mediated killing or opsonization is responsible for control of pathogen during the intermittent extracellular phase of its replication cycle within the vertebrate host [80].

Parasites like Leishmania donovoni, L. chagasi, Toxoplasma gonodii (T. gonodii), T. cruzi, and Plasmodium falciparum can manipulate the costimulatory molecules for evading immune system. L. donovani and L. chagasi infect macrophages and are reported to downregulate both CD80 and ICAM-1 [21], [81]. Such APCs fail to optimally activate T cells. T. gondii and T. cruzi, selectively dampen the exhibition of CD80 and CD28, respectively to impair the function of T cells [82]. CD40-CD40L signaling is crucial for Th1 immunity against L. major, because CD40L/CD40 knockout mice sparsely secrete IL-12, favoring Th2-biased response [83], [84]. Interestingly, L. major can differentially modulate the expression of CD40 and thus anergizes T cells and promotes Tregs population [83]. Plasmodium interferes in the signaling mechanism of CD40 in DCs [85]. CD40 deficient mice succumb to plasmodium infection. This signifies that this pathway is detrimental in providing sterilizing immunity to parasites, as it activates APCs and protective Th1 responses. In conclusion, parasites can efficiently empower the immune system by dampening the expression of costimulatory molecules.

Mechanism Involved in Immunomodulation of Costimulatory Molecules

Induction of the expression of costimulatory molecules on exposure to various inflammatory cytokines (IL-6, IL-12, TNF-α, IFN-γ) or PAMPS/DAMPs is regulated by transcription factors such as NF-κB, IRF-3, AP-1, NFAT [86], [87]. Activation of these transcription factors is tightly regulated by various kinases or phosphatases that include mitogen-activated protein kinases (MAPKs), TNF receptor-associated factor proteins (TRAF), IL-1 receptor-associated kinase 4 (IRAK4), phosphoinositide 3-kinase (PI3K), and Janus-kinase. For example, triggering of TLR-4 with lipopolysaccharides (LPS) elicits pathways dependent on myeloid differentiation primary response gene 88 (MyD88) and TIR-domain-containing adapter-inducing interferon-β (TRIF). Both the molecules induce downstream signaling to activate MAPKs, NF-κB, and IRF family proteins, which are responsible for the enhanced expression of CD40 and CD86 [86], [88]. Further, T-cell interaction with APC involving TCR and costimulatory molecules activates a plethora of downstream signaling molecules, leading to the induction of the expression of CD40L, PD-1, and CD28 [89], [90].

Intracellular pathogens utilize an array of mechanisms to manipulate costimulatory molecules. Upon infection, pathogens trigger IL-10 secretion by inhibiting p38MAP kinases and promoting ERK phosphorylation [91]. IL-10 blocks the degradation of IκB-α that inhibits the NF-κB activation eventually inhibiting the expression of costimulatory molecules [92]. Interference in TLRs signaling by the intracellular pathogens is considered to be a foremost event in the suppression of costimulatory molecules. Mannosylated lipoarabinomannan (ManLAM) of Mtb binds to DC-SIGN and compromises the LPS-induced activation of DCs by interfering in the TLRs' signalling [93]. Binding of Mtb early secreted antigenic target protein 6 (ESAT-6) to TLR-2 activates AKT and prevents interaction between the MyD88 and IRAK4, consequently abrogating NF-κB activation that suppresses CD80 expression [94]. Similarly, HIV upregulates PDL-1 on DCs and monocytes by attenuating the signaling of TLR-7 and TLR-8 [95]. In addition, HIV-mediated PI3K activation upregulates PDL-1 on APCs and thus suppresses the activation of HIV-specific CD8+ T cells [96]. Rapid endocytosis of costimulatory molecules upon infection is suggested as one of the mechanisms to interrupt the function of APCs. For instance, Nef protein of HIV modulates the actin-dependent trafficking mechanism to remove CD80/CD86 from the monocytes surface, making them inefficient to activate T cells [97].

TCR signaling is central for the optimum expression of costimulatory molecules and effector function of T cells. Therefore, it may serve as an important target for pathogens to paralyze T-cell activity [98]. Mtb glycolipids interfere with TCR signaling and block the activation of CD4+ T cells [99]. HIV gp120 interacts with CD4 (a coreceptor for TCR) that inhibits intracellular signal transduction through TCR, leading to decreased hydrolysis of polyphosphoinositide (PI), Ca2+ influx, activation of protein kinase C (PKC), and eventually failure of NFAT translocation. These events culminate in the inhibition of CD40L expression. Decline of CD40L on T cells abrogates the bidirectional signaling and reduces the exhibition of CD80 on APCs [100]. In contrast, Nef activates NFAT and stimulates IL-2 release to overcome the exogenous requirement of IL-2 to promote T-cell proliferation, consequently disseminating the infection [101]. However, Nef retards CD28 and CD4 expression, thereby making T cells incapable of promoting CMI [98]. Corroborative with these observations, Nef-mutated HIV is unable to cause persistent infection. Similarly, core protein of HCV inhibits TCR signaling and upregulates PD-1 [102]. The above-mentioned mechanisms imply that pathogens can effectively utilize various costimulatory pathways to subvert immune response to persist in the host.

Therapeutic Implications

The noncompliance with the relatively high dose and extended therapeutic regime reduces the effectiveness of current drugs, leading to global emergence of MDR/XDR/TDR pathogenic strains. Interestingly, costimulatory molecules have been suggested for therapeutic intervention to treat lymphoma patients [4], [103]. To develop alternative or adjunct (with drugs) therapies, an intensive effort has been undertaken in last decade to understand how intracellular pathogens exploit costimulatory molecules, which are the tour de force of the immune system [27], [31], [68], [78]. The potent role of costimulatory molecules is aptly established in the optimum activation of T cells and APCs; the cells that play a cardinal role in curbing the infections. Hence, immunotherapy involving costimulatory molecules can be a breakthrough strategy to treat various diseases, minimizing side effects inflicted by drug therapies and in restricting the emergence of drug resistance.

Acknowledgments

We are thankful to S. Subramanian, S. Sathyabama, D. Sarkar, M. Amir, and A. Vidyarthi for helping in the preparation of the manuscript.

References

  1. 1. Finlay BB, McFadden G (2006) Anti-immunology: evasion of the host immune system by bacterial and viral pathogens. Cell 124: 767–782.
  2. 2. Curtsinger JM, Mescher MF (2010) Inflammatory cytokines as a third signal for T cell activation. Curr Opin Immunol 22: 333–340.
  3. 3. Jenkins MK (1994) The ups and downs of T cell costimulation. Immunity 1: 443–446.
  4. 4. Suvas S, Singh V, Sahdev S, Vohra H, Agrewala JN (2002) Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma. J Biol Chem 277: 7766–7775.
  5. 5. Gowthaman U, Chodisetti SB, Agrewala JN (2010) T cell help to B cells in germinal centers: putting the jigsaw together. Int Rev Immunol 29: 403–420.
  6. 6. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, et al. (1996) Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 184: 747–752.
  7. 7. Orabona C, Grohmann U, Belladonna ML, Fallarino F, Vacca C, et al. (2004) CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Nat Immunol 5: 1134–1142.
  8. 8. Banchereau J, Bazan F, Blanchard D, Briere F, Galizzi JP, et al. (1994) The CD40 antigen and its ligand. Annu Rev Immunol 12: 881–922.
  9. 9. De Keersmaecker B, Heirman C, Corthals J, Empsen C, van Grunsven LA, et al. (2011) The combination of 4-1BBL and CD40L strongly enhances the capacity of dendritic cells to stimulate HIV-specific T cell responses. J Leukoc Biol 89: 989–999.
  10. 10. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, et al. (1994) CTLA-4 can function as a negative regulator of T cell activation. Immunity 1: 405–413.
  11. 11. Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26: 677–704.
  12. 12. Krutzik SR, Sieling PA, Modlin RL (2001) The role of Toll-like receptors in host defense against microbial infection. Curr Opin Immunol 13: 104–108.
  13. 13. Cooper AM (2009) Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 27: 393–422.
  14. 14. Boise LH, Minn AJ, Noel PJ, June CH, Accavitti MA, et al. (1995) CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 3: 87–98.
  15. 15. Grewal IS, Flavell RA (1996) The role of CD40 ligand in costimulation and T-cell activation. Immunol Rev 153: 85–106.
  16. 16. Schreiber HA, Hulseberg PD, Lee J, Prechl J, Barta P, et al. (2010) Dendritic cells in chronic mycobacterial granulomas restrict local anti-bacterial T cell response in a murine model. PLoS One. 5. doi:10.1371/journal.pone.0011453.
    • 17. Bonato VL, Medeiros AI, Lima VM, Dias AR, Faccioliti LH, et al. (2001) Downmodulation of CD18 and CD86 on macrophages and VLA-4 on lymphocytes in experimental tuberculosis. Scand J Immunol 54: 564–573.
    • 18. Pecora ND, Fulton SA, Reba SM, Drage MG, Simmons DP, et al. (2009) Mycobacterium bovis BCG decreases MHC-II expression in vivo on murine lung macrophages and dendritic cells during aerosol infection. Cell Immunol 254: 94–104.
    • 19. Henderson RA, Watkins SC, Flynn JL (1997) Activation of human dendritic cells following infection with Mycobacterium tuberculosis. J Immunol 159: 635–643.
    • 20. Saha B, Das G, Vohra H, Ganguly NK, Mishra GC (1994) Macrophage-T cell interaction in experimental mycobacterial infection. Selective regulation of co-stimulatory molecules on Mycobacterium-infected macrophages and its implication in the suppression of cell-mediated immune response. Eur J Immunol 24: 2618–2624.
    • 21. Agrewala JN, Kumar B, Vohra H (1998) Potential role of B7-1 and CD28 molecules in immunosuppression in leprosy. Clin Exp Immunol 111: 56–63.
    • 22. Fuse S, Zhang W, Usherwood EJ (2008) Control of memory CD8+ T cell differentiation by CD80/CD86-CD28 costimulation and restoration by IL-2 during the recall response. J Immunol 180: 1148–1157.
    • 23. Bhatt K, Uzelac A, Mathur S, McBride A, Potian J, et al. (2009) B7 costimulation is critical for host control of chronic Mycobacterium tuberculosis infection. J Immunol 182: 3793–3800.
    • 24. Herold KC, Lu J, Rulifson I, Vezys V, Taub D, et al. (1997) Regulation of C-C chemokine production by murine T cells by CD28/B7 costimulation. J Immunol 159: 4150–4153.
    • 25. Arias MA, Jaramillo G, Lopez YP, Mejia N, Mejia C, et al. (2007) Mycobacterium tuberculosis antigens specifically modulate CCR2 and MCP-1/CCL2 on lymphoid cells from human pulmonary hilar lymph nodes. J Immunol 179: 8381–8391.
    • 26. Kan-Sutton C, Jagannath C, Hunter RL Jr (2009) Trehalose 6,6′-dimycolate on the surface of Mycobacterium tuberculosis modulates surface marker expression for antigen presentation and costimulation in murine macrophages. Microbes Infect 11: 40–48.
    • 27. Singh B, Singh G, Trajkovic V, Sharma P (2003) Intracellular expression of Mycobacterium tuberculosis-specific 10-kDa antigen down-regulates macrophage B7.1 expression and nitric oxide release. Clin Exp Immunol 134: 70–77.
    • 28. Grewal IS, Borrow P, Pamer EG, Oldstone MB, Flavell RA (1997) The CD40-CD154 system in anti-infective host defense. Curr Opin Immunol 9: 491–497.
    • 29. Yamauchi PS, Bleharski JR, Uyemura K, Kim J, Sieling PA, et al. (2000) A role for CD40-CD40 ligand interactions in the generation of type 1 cytokine responses in human leprosy. J Immunol 165: 1506–1512.
    • 30. Murray RA, Siddiqui MR, Mendillo M, Krahenbuhl J, Kaplan G (2007) Mycobacterium leprae inhibits dendritic cell activation and maturation. J Immunol 178: 338–344.
    • 31. Samten B, Thomas EK, Gong J, Barnes PF (2000) Depressed CD40 ligand expression contributes to reduced gamma interferon production in human tuberculosis. Infect Immun 68: 3002–3006.
    • 32. Campos-Neto A, Ovendale P, Bement T, Koppi TA, Fanslow WC, et al. (1998) CD40 ligand is not essential for the development of cell-mediated immunity and resistance to Mycobacterium tuberculosis. J Immunol 160: 2037–2041.
    • 33. Lazarevic V, Myers AJ, Scanga CA, Flynn JL (2003) CD40, but not CD40L, is required for the optimal priming of T cells and control of aerosol M. tuberculosis infection. Immunity 19: 823–835.
    • 34. Stewart GR, Snewin VA, Walzl G, Hussell T, Tormay P, et al. (2001) Overexpression of heat-shock proteins reduces survival of Mycobacterium tuberculosis in the chronic phase of infection. Nat Med 7: 732–737.
    • 35. Sakai S, Kawamura I, Okazaki T, Tsuchiya K, Uchiyama R, et al. (2010) PD-1-PD-L1 pathway impairs T(h)1 immune response in the late stage of infection with Mycobacterium bovis bacillus Calmette-Guerin. Int Immunol 22: 915–925.
    • 36. Jurado JO, Alvarez IB, Pasquinelli V, Martinez GJ, Quiroga MF, et al. (2008) Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis. J Immunol 181: 116–125.
    • 37. Alvarez IB, Pasquinelli V, Jurado JO, Abbate E, Musella RM, et al. (2010) Role played by the programmed death-1-programmed death ligand pathway during innate immunity against Mycobacterium tuberculosis. J Infect Dis 202: 524–532.
    • 38. Lazar-Molnar E, Chen B, Sweeney KA, Wang EJ, Liu W, et al. (2010) Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis. Proc Natl Acad Sci U S A 107: 13402–13407.
    • 39. Barber DL, Mayer-Barber KD, Feng CG, Sharpe AH, Sher A (2010) CD4 T cells promote rather than control tuberculosis in the absence of PD-1-mediated inhibition. J Immunol 186: 1598–1607.
    • 40. Hanekom WA, Mendillo M, Manca C, Haslett PA, Siddiqui MR, et al. (2003) Mycobacterium tuberculosis inhibits maturation of human monocyte-derived dendritic cells in vitro. J Infect Dis 188: 257–266.
    • 41. Shortman K, Heath WR (2001) Immunity or tolerance? That is the question for dendritic cells. Nat Immunol 2: 988–989.
    • 42. Levings MK, Sangregorio R, Roncarolo MG (2001) Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 193: 1295–1302.
    • 43. Anderson KM, Czinn SJ, Redline RW, Blanchard TG (2006) Induction of CTLA-4-mediated anergy contributes to persistent colonization in the murine model of gastric Helicobacter pylori infection. J Immunol 176: 5306–5313.
    • 44. Yao T, Mecsas J, Healy JI, Falkow S, Chien Y (1999) Suppression of T and B lymphocyte activation by a Yersinia pseudotuberculosis virulence factor, yopH. J Exp Med 190: 1343–1350.
    • 45. Pryjma J, Baran J, Ernst M, Woloszyn M, Flad HD (1994) Altered antigen-presenting capacity of human monocytes after phagocytosis of bacteria. Infect Immun 62: 1961–1967.
    • 46. Wyant TL, Tanner MK, Sztein MB (1999) Potent immunoregulatory effects of Salmonella typhi flagella on antigenic stimulation of human peripheral blood mononuclear cells. Infect Immun 67: 1338–1346.
    • 47. Das S, Suarez G, Beswick EJ, Sierra JC, Graham DY, et al. (2006) Expression of B7-H1 on gastric epithelial cells: its potential role in regulating T cells during Helicobacter pylori infection. J Immunol 176: 3000–3009.
    • 48. Beswick EJ, Pinchuk IV, Das S, Powell DW, Reyes VE (2007) Expression of the programmed death ligand 1, B7-H1, on gastric epithelial cells after Helicobacter pylori exposure promotes development of CD4+ CD25+ FoxP3+ regulatory T cells. Infect Immun 75: 4334–4341.
    • 49. Skinner JA, Reissinger A, Shen H, Yuk MH (2004) Bordetella type III secretion and adenylate cyclase toxin synergize to drive dendritic cells into a semimature state. J Immunol 173: 1934–1940.
    • 50. Ross PJ, Lavelle EC, Mills KH, Boyd AP (2004) Adenylate cyclase toxin from Bordetella pertussis synergizes with lipopolysaccharide to promote innate interleukin-10 production and enhances the induction of Th2 and regulatory T cells. Infect Immun 72: 1568–1579.
    • 51. Everett H, McFadden G (1999) Apoptosis: an innate immune response to virus infection. Trends Microbiol 7: 160–165.
    • 52. Price DA, Klenerman P, Booth BL, Phillips RE, Sewell AK (1999) Cytotoxic T lymphocytes, chemokines and antiviral immunity. Immunol Today 20: 212–216.
    • 53. World Health Organization (2010) Global health observatory (GHO). Available: http://www.who.int/gho/hiv/en/index.html Accessed 5 June 2012.
      • 54. Davis CB, Dikic I, Unutmaz D, Hill CM, Arthos J, et al. (1997) Signal transduction due to HIV-1 envelope interactions with chemokine receptors CXCR4 or CCR5. J Exp Med 186: 1793–1798.
      • 55. Geijtenbeek TB, van Kooyk Y (2003) DC-SIGN: a novel HIV receptor on DCs that mediates HIV-1 transmission. Curr Top Microbiol Immunol 276: 31–54.
      • 56. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, et al. (2002) HIV preferentially infects HIV-specific CD4+ T cells. Nature 417: 95–98.
      • 57. Rowland-Jones S (1999) HIV infection: where have all the T cells gone? Lancet 354: 5–7.
      • 58. Kornbluth RS (2002) An expanding role for CD40L and other tumor necrosis factor superfamily ligands in HIV infection. J Hematother Stem Cell Res 11: 787–801.
      • 59. Smed-Sorensen A, Lore K, Walther-Jallow L, Andersson J, Spetz AL (2004) HIV-1-infected dendritic cells up-regulate cell surface markers but fail to produce IL-12 p70 in response to CD40 ligand stimulation. Blood 104: 2810–2817.
      • 60. Kornbluth RS (2000) The emerging role of CD40 ligand in HIV infection. J Leukoc Biol 68: 373–382.
      • 61. Qiao X, He B, Chiu A, Knowles DM, Chadburn A, et al. (2006) Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells. Nat Immunol 7: 302–310.
      • 62. Cagigi A, Nilsson A, Pensieroso S, Chiodi F (2010) Dysfunctional B-cell responses during HIV-1 infection: implication for influenza vaccination and highly active antiretroviral therapy. Lancet Infect Dis 10: 499–503.
      • 63. De Milito A, Nilsson A, Titanji K, Thorstensson R, Reizenstein E, et al. (2004) Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection. Blood 103: 2180–2186.
      • 64. Boudet F, Lecoeur H, Gougeon ML (1996) Apoptosis associated with ex vivo down-regulation of Bcl-2 and up-regulation of Fas in potential cytotoxic CD8+ T lymphocytes during HIV infection. J Immunol 156: 2282–2293.
      • 65. Gehri R, Hahn S, Rothen M, Steuerwald M, Nuesch R, et al. (1996) The Fas receptor in HIV infection: expression on peripheral blood lymphocytes and role in the depletion of T cells. Aids 10: 9–16.
      • 66. Dolfi DV, Duttagupta PA, Boesteanu AC, Mueller YM, Oliai CH, et al. (2011) Dendritic cells and CD28 costimulation are required to sustain virus-specific CD8+ T cell responses during the effector phase in vivo. J Immunol 186: 4599–4608.
      • 67. Chaudhry A, Das SR, Hussain A, Mayor S, George A, et al. (2005) The Nef protein of HIV-1 induces loss of cell surface costimulatory molecules CD80 and CD86 in APCs. J Immunol 175: 4566–4574.
      • 68. Venkatachari NJ, Majumder B, Ayyavoo V (2007) Human immunodeficiency virus (HIV) type 1 Vpr induces differential regulation of T cell costimulatory molecules: direct effect of Vpr on T cell activation and immune function. Virology 358: 347–356.
      • 69. De Keersmaecker B, Thielemans K, Aerts JL (2011) Fighting with the enemy's weapons? the role of costimulatory molecules in HIV. Curr Mol Med 11: 172–196.
      • 70. Servet-Delprat C, Vidalain PO, Bausinger H, Manie S, Le Deist F, et al. (2000) Measles virus induces abnormal differentiation of CD40 ligand-activated human dendritic cells. J Immunol 164: 1753–1760.
      • 71. Salio M, Cella M, Suter M, Lanzavecchia A (1999) Inhibition of dendritic cell maturation by herpes simplex virus. Eur J Immunol 29: 3245–3253.
      • 72. Auffermann-Gretzinger S, Keeffe EB, Levy S (2001) Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood 97: 3171–3176.
      • 73. Coscoy L, Ganem D (2001) A viral protein that selectively downregulates ICAM-1 and B7-2 and modulates T cell costimulation. J Clin Invest 107: 1599–1606.
      • 74. Wherry EJ (2011) T cell exhaustion. Nat Immunol 12: 492–499.
      • 75. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, et al. (2006) PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443: 350–354.
      • 76. Petrovas C, Casazza JP, Brenchley JM, Price DA, Gostick E, et al. (2006) PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med 203: 2281–2292.
      • 77. Chikuma S, Terawaki S, Hayashi T, Nabeshima R, Yoshida T, et al. (2009) PD-1-mediated suppression of IL-2 production induces CD8+ T cell anergy in vivo. J Immunol 182: 6682–6689.
      • 78. Trabattoni D, Saresella M, Biasin M, Boasso A, Piacentini L, et al. (2003) B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression. Blood 101: 2514–2520.
      • 79. Chen L, Zhang Z, Chen W, Zhang Z, Li Y, et al. (2007) B7-H1 up-regulation on myeloid dendritic cells significantly suppresses T cell immune function in patients with chronic hepatitis B. J Immunol 178: 6634–6641.
      • 80. Hall BF, Joiner KA (1991) Strategies of obligate intracellular parasites for evading host defences. Immunol Today 12: A22–27.
      • 81. Kaye PM, Rogers NJ, Curry AJ, Scott JC (1994) Deficient expression of co-stimulatory molecules on Leishmania-infected macrophages. Eur J Immunol 24: 2850–2854.
      • 82. Fischer HG, Dorfler R, Schade B, Hadding U (1999) Differential CD86/B7-2 expression and cytokine secretion induced by Toxoplasma gondii in macrophages from resistant or susceptible BALB H-2 congenic mice. Int Immunol 11: 341–349.
      • 83. Campbell KA, Ovendale PJ, Kennedy MK, Fanslow WC, Reed SG, et al. (1996) CD40 ligand is required for protective cell-mediated immunity to Leishmania major. Immunity 4: 283–289.
      • 84. Martin S, Agarwal R, Murugaiyan G, Saha B (2010) CD40 expression levels modulate regulatory T cells in Leishmania donovani infection. J Immunol 185: 551–559.
      • 85. Mukherjee P, Chauhan VS (2008) Plasmodium falciparum-free merozoites and infected RBCs distinctly affect soluble CD40 ligand-mediated maturation of immature monocyte-derived dendritic cells. J Leukoc Biol 84: 244–254.
      • 86. Qin H, Wilson CA, Lee SJ, Zhao X, Benveniste EN (2005) LPS induces CD40 gene expression through the activation of NF-kappaB and STAT-1alpha in macrophages and microglia. Blood 106: 3114–3122.
      • 87. Terawaki S, Chikuma S, Shibayama S, Hayashi T, Yoshida T, et al. (2011) IFN-alpha directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol 186: 2772–2779.
      • 88. Lim W, Gee K, Mishra S, Kumar A (2005) Regulation of B7.1 costimulatory molecule is mediated by the IFN regulatory factor-7 through the activation of JNK in lipopolysaccharide-stimulated human monocytic cells. J Immunol 175: 5690–5700.
      • 89. Jaiswal AI, Dubey C, Swain SL, Croft M (1996) Regulation of CD40 ligand expression on naive CD4 T cells: a role for TCR but not co-stimulatory signals. Int Immunol 8: 275–285.
      • 90. Lenschow DJ, Walunas TL, Bluestone JA (1996) CD28/B7 system of T cell costimulation. Annu Rev Immunol 14: 233–258.
      • 91. Rub A, Dey R, Jadhav M, Kamat R, Chakkaramakkil S, et al. (2009) Cholesterol depletion associated with Leishmania major infection alters macrophage CD40 signalosome composition and effector function. Nat Immunol 10: 273–280.
      • 92. Ding L, Linsley PS, Huang LY, Germain RN, Shevach EM (1993) IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 151: 1224–1234.
      • 93. Geijtenbeek TB, Van Vliet SJ, Koppel EA, Sanchez-Hernandez M, Vandenbroucke-Grauls CM, et al. (2003) Mycobacteria target DC-SIGN to suppress dendritic cell function. J Exp Med 197: 7–17.
      • 94. Pathak SK, Basu S, Basu KK, Banerjee A, Pathak S, et al. (2007) Direct extracellular interaction between the early secreted antigen ESAT-6 of Mycobacterium tuberculosis and TLR2 inhibits TLR signaling in macrophages. Nat Immunol 8: 610–618.
      • 95. Meier A, Bagchi A, Sidhu HK, Alter G, Suscovich TJ, et al. (2008) Upregulation of PD-L1 on monocytes and dendritic cells by HIV-1 derived TLR ligands. AIDS 22: 655–658.
      • 96. Muthumani K, Shedlock DJ, Choo DK, Fagone P, Kawalekar OU, et al. (2010) HIV-mediated phosphatidylinositol 3-kinase/serine-threonine kinase activation in APCs leads to programmed death-1 ligand upregulation and suppression of HIV-specific CD8 T cells. J Immunol 187: 2932–2943.
      • 97. Chaudhry A, Das SR, Jameel S, George A, Bal V, et al. (2007) A two-pronged mechanism for HIV-1 Nef-mediated endocytosis of immune costimulatory molecules CD80 and CD86. Cell Host Microbe 1: 37–49.
      • 98. Swigut T, Shohdy N, Skowronski J (2001) Mechanism for down-regulation of CD28 by Nef. Embo J 20: 1593–1604.
      • 99. Mahon RN, Rojas RE, Fulton SA, Franko JL, Harding CV, et al. (2009) Mycobacterium tuberculosis cell wall glycolipids directly inhibit CD4+ T-cell activation by interfering with proximal T-cell-receptor signaling. Infect Immun 77: 4574–4583.
      • 100. Chirmule N, McCloskey TW, Hu R, Kalyanaraman VS, Pahwa S (1995) HIV gp120 inhibits T cell activation by interfering with expression of costimulatory molecules CD40 ligand and CD80 (B71). J Immunol 155: 917–924.
      • 101. Manninen A, Renkema GH, Saksela K (2000) Synergistic activation of NFAT by HIV-1 nef and the Ras/MAPK pathway. J Biol Chem 275: 16513–16517.
      • 102. Yao ZQ, King E, Prayther D, Yin D, Moorman J (2007) T cell dysfunction by hepatitis C virus core protein involves PD-1/PDL-1 signaling. Viral Immunol 20: 276–287.
      • 103. Leonard JP, Friedberg JW, Younes A, Fisher D, Gordon LI, et al. (2007) A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol 18: 1216–1223.
      • 104. Agrawal A, Lingappa J, Leppla SH, Agrawal S, Jabbar A, et al. (2003) Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin. Nature 424: 329–334.
      • 105. Chou PJ, Newton CA, Perkins I, Friedman H, Klein TW (2008) Suppression of dendritic cell activation by anthrax lethal toxin and edema toxin depends on multiple factors including cell source, stimulus used, and function tested. DNA Cell Biol 27: 637–648.
      • 106. Mitchell P, Germain C, Fiori PL, Khamri W, Foster GR, et al. (2007) Chronic exposure to Helicobacter pylori impairs dendritic cell function and inhibits Th1 development. Infect Immun 75: 810–819.
      • 107. Saha B, Das G, Vohra H, Ganguly NK, Mishra GC (1995) Macrophage-T cell interaction in experimental visceral leishmaniasis: failure to express costimulatory molecules on Leishmania-infected macrophages and its implication in the suppression of cell-mediated immunity. Eur J Immunol 25: 2492–2498.